SOURCE: Theravance, Inc.

Theravance, Inc.

November 04, 2015 16:05 ET

Theravance to Present at Two Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 4, 2015) -  Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, will present at two upcoming conferences in November 2015:

Credit Suisse Healthcare Conference
Wednesday, November 11 at 7:30 a.m. MST, Scottsdale, AZ

Stifel Nicolaus Healthcare Conference
Wednesday, November 18 at 1:30 p.m. EST, New York, NY

A live audio webcast of the presentations will be available on the company's website at http://investor.thrxinc.com/events.cfm and will be archived there for 30 days. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

About Theravance

Theravance, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the agreement with GSK, Theravance is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Theravance retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Theravance's website at www.thrxinc.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(THRX-F)

Contact Information